| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_85acbcf556e8a2b3023ab70f44e199c8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 |
| filingDate |
1994-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c4bd0b03415cf782e8b6241b1595223
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_840edc7dd5eceb975d9db582ca1b296f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04d1dfa33157de3ead792d68f8dee60f |
| publicationDate |
1995-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9508991-A1 |
| titleOfInvention |
Parenteral busulfan for treatment of malignant disease |
| abstract |
Stable parenteral formulations of busulfan safe for parenteral administration. An HPLC assay for busulfan sensitive enough to dependably quantitate concentrations in plasma as low as approximately 100 ng/ml was developed. The stability of these formulations was investigated to select preparations providing desirable plasma pharmacokinetic parameters with parenteral versus oral administration. In addition, quantitative extraction technology was established for reliable quantification of bulsulfan in plasma samples after both oral and parenteral drug administration. When administered to experimental animals, the parenteral busulfan formulation yielded significantly higher plasma drug concentrations and higher area under the plasma concentration vs. time curve than did the oral (standard) tablet preparation. The improved bioavailability of the parenteral formulation optimizes high dose busulfan thepary against malignant disease and improves the safety of such therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018204535-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9965481-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7351427-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110831588-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2787621-C2 |
| priorityDate |
1993-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |